Related Experiment Video

Updated: Jul 5, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Management of patients with resistant or refractory chronic myelogenous leukemia

Alfonso Quintás-Cardama1, Jorge Cortes

  • 1Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.

Oncology (Williston Park, N.Y.)
|May 14, 2008
PubMed

Insights

Imatinib resistance in chronic myeloid leukemia (CML) is common, often due to BCR-ABL mutations. Second-generation tyrosine kinase inhibitors like nilotinib and dasatinib offer new hope for patients with refractory CML.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Imatinib mesylate (Gleevec) revolutionized chronic myeloid leukemia (CML) treatment.
  • However, 20-30% of CML patients develop resistance or intolerance to imatinib.
  • BCR-ABL oncogene mutations are a primary cause of imatinib resistance.

Purpose of the Study:

  • To review the causes and consequences of imatinib resistance in CML.
  • To discuss the management of imatinib-refractory CML.
  • To highlight the role of second-generation tyrosine kinase inhibitors (TKIs).

Main Methods:

  • Literature review of studies on imatinib resistance in CML.
  • Analysis of clinical trial data for second-generation TKIs.
  • Discussion of pharmacokinetic and pharmacodynamic profiles of TKIs.

Main Results:

  • Imatinib resistance is frequently linked to BCR-ABL mutations.
  • Second-generation TKIs, including nilotinib and dasatinib, show efficacy in resistant CML.
  • These TKIs have distinct profiles that may overcome resistance mechanisms.

Conclusions:

  • Imatinib resistance presents a significant challenge in CML management.
  • Second-generation TKIs represent a crucial advancement for refractory CML patients.
  • Further research is ongoing to optimize TKI therapy for CML.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Modeling Chemotherapy Resistant Leukemia In Vitro08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...